share_log

三葉草生物-B：(經修訂)截至2024年6月30日止月份股份發行人的證券變動月報表

CLOVER BIO-B: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2024

Hong Kong Stock Exchange ·  Jul 17 22:04
Summary by Futu AI
三葉草生物製藥有限公司（三叶草生物-B）於2024年7月17日重新提交了截至2024年6月30日的股份變動月報表。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。已發行股份（不包括庫存股份）從上月底的1,297,047,429股增加至1,297,048,929股，增加了1,500股。這些新增股份是由於行使股份期權所得。公司的首次公開發售前購股權計劃於2021年4月15日獲股東大會通過，而首次公開發售後購股權計劃則於2021年9月26日獲通過。報告中未提及有關香港預託證券的資料，並確認所有證券發行均遵守相關上市規則及法律規定。
三葉草生物製藥有限公司（三叶草生物-B）於2024年7月17日重新提交了截至2024年6月30日的股份變動月報表。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。已發行股份（不包括庫存股份）從上月底的1,297,047,429股增加至1,297,048,929股，增加了1,500股。這些新增股份是由於行使股份期權所得。公司的首次公開發售前購股權計劃於2021年4月15日獲股東大會通過，而首次公開發售後購股權計劃則於2021年9月26日獲通過。報告中未提及有關香港預託證券的資料，並確認所有證券發行均遵守相關上市規則及法律規定。
On July 17th, 2024, Three Leaf Clover Biopharmaceutical Co., Ltd. (Three Leaf Clover Biopharmaceutical-B) resubmitted the monthly shareholding change report as of June 30th, 2024. The report shows that the company's statutory/registered share capital balance remained at 2,000,000,000 shares, with a par value of $0.0001 per share, for a total of $200,000. The number of issued shares (excluding treasury shares) increased from 1,297,047,429 shares at the end of last month to 1,297,048,929 shares, an increase of 1,500 shares. These new shares were obtained through the exercise of share options. The company's pre-IPO share purchase plan was approved by the shareholders' meeting on April 15th, 2021, while the post-IPO share purchase plan was approved on September 26th, 2021. The report did not mention any information regarding Hong Kong depositary receipts and confirmed that all securities issuances comply with relevant listing rules and legal regulations.
On July 17th, 2024, Three Leaf Clover Biopharmaceutical Co., Ltd. (Three Leaf Clover Biopharmaceutical-B) resubmitted the monthly shareholding change report as of June 30th, 2024. The report shows that the company's statutory/registered share capital balance remained at 2,000,000,000 shares, with a par value of $0.0001 per share, for a total of $200,000. The number of issued shares (excluding treasury shares) increased from 1,297,047,429 shares at the end of last month to 1,297,048,929 shares, an increase of 1,500 shares. These new shares were obtained through the exercise of share options. The company's pre-IPO share purchase plan was approved by the shareholders' meeting on April 15th, 2021, while the post-IPO share purchase plan was approved on September 26th, 2021. The report did not mention any information regarding Hong Kong depositary receipts and confirmed that all securities issuances comply with relevant listing rules and legal regulations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.